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SUMMARY
The influence of coenzyme Q10 (CoQ10) in cold stress test (-15°C for 4 hours) cardiac
functional impairment was studied in isolated isovolumic heart of control rats (C; n=12)
and of placebo (P; n=11) and treated rats (CoQ10; n=10). In addition, electron microscopic
evaluation of left ventricular (LV) slices (n=3 in each group) allowed us to analyze the
myocardial ultrastructure. Maximal values of developed pressure (DPmax) were similarly
decreased in cold stressed animals (C=129±3.9 mmHg; P=106±6.7 mmHg; CoQ10=91±
3.9 mmHg); however, volume-induced enhancement of pressure generation (slope of DP
/ volume relations: C=0.248±0.0203 mmHg / µl; P=0.2831±0.0187 mmHg / µl;
CoQ10=0.2387 ( 0.0225 mmHg / µl; p > 0.05), and the duration of systole (C=80±1.6 ms;
P=78±1.3 ms; CoQ10=80±2.7 ms) were not altered. Myocardial relaxation, evaluated by
the relaxation constant (C=39±1.9 ms; P=42±3.4 ms; CoQ10=51±6.0 ms), as well as rest-
ing stress / strain relations were unaffected by cold stress. Myocardial samples showed
that pretreatment with CoQ10 attenuates myofibrillar and mitochondrial lesions, and pre-
vents mitochondrial fractional area increase (P: 53.11%>CoQ10: 38.78%=C: 33.87%; p<
0.005) indicating that the exogenous administration of CoQ10 can reduce cold stress myo-
cardial injury. (Jpn Heart J 2001; 42: 327-338)
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CONSOLIDATED data from the literature point towards the existence of myo-
cardial structural lesions resulting from the exposure of animals to extreme low
temperatures.1-4) More frequently, the structural myocardial lesion described is
characterized by vacuolization of mitochondrial cristae and myofilament disar-
rangement.1-4) The sharp increase of circulating cathecolamines is likely to be a
factor in myocardial lesions.5-8) It has been demonstrated that previous adminis-
tration of propanolol prevents cold stress test induced structural changes.4) To our
knowledge, there is only one paper describing the sole influence of profound sys-
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temic cold stress on ventricular function; decreases of contraction amplitude, and
myocardial stiffness of isolated rat heart.9) Other papers analyzing the action of
hypothermia over cardiac function attempted to assess myocardial preservation in
a surgical setting and in these studies hypothermia was always associated with
ischemia and reperfusion injury.
Coenzyme Q10 (CoQ10) is an enzyme naturally synthesized by the organism
as a mobile electron carrier in the mitochondrial electron-transfer process of res-
piration and coupled phosphorylation. CoQ10 has been shown to prevent cardiac
injury resulting from sustained tachycardia,10) adriamycin toxicity11,12) and
ischemia / reperfusion.1,13-19) It has been demonstrated that the exogenous admin-
istration of CoQ10 blocks lipid peroxidation,20-22) reduces depletion of ATP,16,19)
improves high-energy phosphate restoration of postischemic reperfusion,14,19) and
reduces mitochondrial calcium overload due to ischemia reperfusion.1) Its ability
to scavenge oxygen free radicals has also been suggested.20) Ultrastructurally,
CoQ10 has been shown to prevent mitochondrial deformity during episodes of
ischemia. Nayler and al1) demonstrated that pretreatment of animals with CoQ10
was able to maintain mitochondrial architecture, compared with nontreated ani-
mals, which showed edema, cell membrane disruption, mitochondrial lysis, and
disorganization of myofibrils during postischemic reperfusion.1) To our knowl-
edge, no report has analyzed the action of CoQ10 action on myocardial structural
and functional lesions resulting from cold stress test. 
The purpose of this paper was to analyze the action of myocardial injury
resulting from cold stress test on cardiac mechanics as well as the modifications
caused by CoQ10 on functional and ultrastructural changes. In the clinical setting,
the results may lead to an understanding of whether the exogenous administration
of CoQ10 protects the myocardium from injuries. In isolated isovolumic rat hearts
systolic and diastolic function parameters were analyzed and the ultrastructural
aspects were assessed by electron microscopy.
MATERIALS AND METHODS
Animals: The study was conducted on 42 male Wistar rats weighing 250-300 g.
Thirty-three animals were used for functional data assessment and 9 for the ultra-
structural parameters. Rats were matched in one of the three experimental group-
ings: a) CONTROL (C; n=15): those in this group received 1 ml of Ubiquinone
vehicle (carboxymethyl cellulose+methylparaben+propyl paraben), by gastric
gavage, for five days prior to the cold stress test. Twelve rats were used for func-
tional data definition, and three for ultrastructure analysis; b) PLACEBO (P;
n=14): those rats received 1 ml of vehicle, by gastric gavage, for five days prior
to an experimental procedure, and were kept in the refrigerator for four hours at
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-15°C. Eleven rats were used in the functional studies and three in the ultrastruc-
ture study; c) COENZYME Q10 (CoQ10; n=13): these rats received 1 ml of solu-
tion  which contained 10 mg of CoQ10 (kindly supplied by Marjan Farma Ltda,
São Paulo, Brazil) for five days preceding the experiment and were kept in the
refrigerator for four hours at regulated -15°C. Ten animals were studied in the
functional assessment experiments, and three in the ultrastructure analysis. 
Immediately after the cold stress test the animals were used in the functional
and ultrastructure evaluations. After intraperitoneal heparinization (500 IU) and
anesthesia (urethane: 1.2 g / kg), the animals underwent a medial thoracotomy,
the ascending aorta was cannulated and the heart perfused at a constant perfusion
pressure of 100 mmHg using the Langendorff technique in a retrograde manner,
with Krebs-Henseleit bicarbonate buffer, pH 7.35-7.45, containing 10 U / l insu-
lin bubbled with 95% O2 and 5% CO2 (PO2>480 mmHg) and warmed to 36°C.
The heart was then quickly removed, the LV cavity vented by apical puncture and
a small collapsed latex balloon was placed inside the LV chamber via the left
atrium. The balloon was connected to a pressure transducer by a short length of
stiff polyethylene tubing to determine LV pressure. The balloon was sufficiently
compliant and its size large enough so as not to contribute to pressure over the
volume range utilized (maximum volume introduced in the balloon: 400 µl). The
right atrium, including the sinus node region, was removed and right ventricular
pacing was carried out using a right ventricular bipolar pacemaker wire driven by
a stimulator delivering 4 ms monophasic square waves of 5 V. A stimulation rate
of 180 beats / minute was used in all experiments. When needed, atrioventricular
(AV) block was effected by mechanical crushing of the AV nodal region to con-
trol heart rate. The LV volume was adjusted in such a way that diastolic pressure
was zero (V0).
After the equilibration period (15 min), a pressure-volume relation was
determined for every heart by measuring LV peak systolic and diastolic pressures
30 s after 20 µl  increments in the balloon volume (saline injected with a 500 µl
Hamilton syringe) until a maximum end diastolic pressure of 40 mmHg was
obtained. An electronic derivative of the LV pressure (dP / dt) was also recorded. 
At the end of the experiments, the left atrium and right ventricular free wall
were removed and the myocardial mass was weighed and taken as the LV wet
weight.
Nine other rats, whose hearts were not perfused, were utilized for ultrastruc-
tural analyzes. Immediately after anesthesia, the thorax of each rat was opened
and the heart was exposed and removed. Cold 2% glutaraldehyde solution was
dropped on the still beating heart. Fragments of the left ventricle wall were then
removed and fixed in phosphate buffered glutaraldehyde at pH 7.2. The frag-
ments were cut into small, 1 mm thick pieces, which were postfixed in 1% OsO4
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solution for 2 h at 4°C, and then dehydrated and embedded in araldite. Silver or
gray thin sections were cut on a Porter-Blum MT-B ultramicrotome, mounted on
copper grids and stained with uranyl acetate and lead citrate. The preparations
were examined through a Philips EM-301 electron microscope and photographed
at 2,000x the original magnification.
A reticule with 1,750 points was superimposed to three representative
microphotographies (14,380X - final magnification) of each rat and the fractional
mitochondrial area was calculated according to the method described by Gunder-
sen, et al.23) The mean of the three measures was considered as representative of
each rat.
Calculations: Developed pressure (DP: systolic pressure minus diastolic pres-
sure) was analyzed and maximal developed pressure (DPmax) was utilized as an
index of maximal contractile capacity. Frank-Starling curves were constructed for
each heart plotting instantaneous developed pressure as a function of the respec-
tive left ventricular volume. The points of the ascending limb of pressure/volume
relations, which maintain a linear relation, were linearly fitting and the slopes of
the straight lines were compared. Systole duration was defined in the pressure
record by the time to peak pressure (TPP: time elapsed from the beginning of con-
traction until maximal value of DP).
Myocardial stiffness was evaluated in all cases. Resting circumferential wall
stress was estimated from ventricular pressure measurements, ventricular volume
and weight as described by Bing, et al.24) A spherical model was assumed, in
which the left ventricular cavity has a radius Ri, and chamber volume (Vc) was
considered to be the sum of the liquid volume inside the balloon plus the latex
volume of the balloon (latex weight / 0.936, the specific gravity of latex
balloon1)). Thus, Vc=4/3 πRi3, and Ri=[Vc / 4 / 3 π]1/3. Total heart volume (con-
tained in a sphere of radius Ri+h) is equal to the sum of Vc and Vwall, where Vwall
is the volume of the LVwall (Vwall=left ventricular net weight / 1.05, the specific
gravity of the myocardium). Therefore, Vc+Vwall=4/3 π (Ri+h)1/3, and
Ri+h=[vc+Vwall / (4/3 π)]1/3. LV diastolic mid-wall circumferential stress (σ) was
then derived from the relationship described by Mirsky25):
σ=(PRi2/h) / (2Ri+h)
where P is resting pressure, Ri is chamber radius and h is wall thickness.
Passive myocardial stiffness curves were established by fitting the resting
stress (σr)-strain (ε) data to a mono-exponential relation σr=A (eKε -1) where A
and K are coefficients.
In order to evaluate myocardial relaxation, the time constant for isovolumic
pressure decline (τ) was calculated according to the equation Pt=P0e−t/τ, where Pt
is LV pressure at time t, and P0 is LV pressure at the peak rate of LV pressure fall
(nadir of dP / dt). Pressure measurements were taken at 10 ms intervals at a paper
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speed of 100 mm / s and linear regression analysis was performed for the plot of
ln Pt vs t. Subsequently, τ was defined as the negative reciprocal of the slope,
according to the equation ln Pt=-t / τ+ln P0. 
Statistical analysis: One way ANOVA complemented by the Newman-Keuls
test was used to detect differences among groups. A p value<0.05 was considered
significant and the results are presented as means±standard error of the means (x±
SEM). 
RESULTS
No differences could be seen between myocardial wet weight (C= 627±8.9
mg; P=619±9.9 mg; CoQ10=649±13 mg; p>0,05) and ventricular volume at zero
diastolic pressure (C=122±9.5 µl; P=106±7.9 µl; CoQ10=112±5.9 µl; p>0.05) for
the three groups.
Functional data: Similar impairment of systolic function was noted for groups
P and CoQ10, since their DPmax (P: 106±6.7 mmHg; CoQ10: 91±3.9 mmHg; Fig-
ure 1A) and dP / dt (P: 2,086±123 mmHg / s; CoQ10: 1,994±99 mmHg / s; Figure
1B) did not differ and were significantly lower (p<0.001) then control hearts (129
±3.9 mmHg and 2,482±80 mmHg / s, respectively). Developed pressures / ven-
tricular volume relations have shown that myocardial sensitivity to stretching has
been preserved in animals submitted to cold stress test (Figure 1C). Although the
P and CoQ10 groups straight lines are seen to be under that of controls, no signif-
Figure 1. Panel A: Individual values (empty symbols), means (filled symbols) and standard error of means (vertical bars) of
maximal developed pressure (DPmax) of hearts of the Control (triangles), Placebo (inverted triangles) and CoQ10 (circles) groups.
Panel B: Individual values (empty symbols), means (filled symbols) and standard error of means (vertical bars) of dP/dt of the
Control (triangles), Placebo (inverted triangles) and CoQ10 (circles) groups. Panel C: Developed pressure (DP) plotted as a func-
tion of ventricular volume of hearts of the Control (triangles), Placebo (inverted triangles) and CoQ10 (circles) groups.
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icant difference between the slopes could be identified in the three groups (C:
0.248±0.02 mmHg / µl; P=0.283±0.018 mmHg / µl; CoQ10=0.238±0.022 mmHg
/ µl; p>0.05). These results indicate that rats submitted to cold stress test had their
contractile capacity decreased all along the Frank-Starling curve, however, the
myocardial sensitivity to stretching was preserved. In addition, no changes were
observed in contraction duration (TPP) for animals submitted to cold stress test
(C=80±1.6 ms; P=78±1.3 ms; CoQ10=80 (2.7 ms; p>0.05).
Diastolic function analyses showed that cold stress did not affect myocardial
relaxation or stiffness. The stress / strain curves for the three groups were super-
imposed (Figure 2A), making the myocardial stiffness calculation (dσr / dε) dis-
pensable. Likewise, no significant differences were identified between the
relaxation constant in the three groups (C: 39±1.9 s; P: 42±3.4 s; CoQ10: 51±6.0
s; p>0.05; Figure 2B).
Figure 2. A: Resting stress (RS)/strain (V-V0/V0) relationships of hearts of Control (triangles), Placebo (inverted
triangles) and CoQ10 (circles) groups. B: Individual values (empty symbols), means (filled symbols) and standard
error of means (vertical bars) of relaxation constant (τ) of hearts of the control (triangles), placebo (inverted triangles)
and CoQ10 (circles) groups.
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Ultrastructure data: The myocardium of the C group animals showed a normal
morphology which consisted of elongated striated muscle cells with preserved
myofibrils and sarcolemma. Interstitial connective tissue components, such as
fibroblasts, collagen fibrils, amorphous intercellular matrix and blood vessels
were observed. The sarcomeres in the sarcoplasm were organized and delimited
by Z bands, and showed slightly fainted I bands and, in some cases, sarcoplasmic
reticulum dilatation. Between the myofibrils or in the sarcoplasm, there was a
high concentration of mitochondria of several sizes and shapes with no structural
changes. Few lipid droplets were also observed in the sarcoplasm.
The P group cardiac fibers (Figure 3A and 3B) presented areas in which the
myofibrils were well preserved, with a structural pattern similar to normal, and
numerous areas with focal loss of myofibrils. Relaxation of the sarcomeres was
also observed, characterized by enlargement of I bands. A great number of mito-
chondria showed alterations of different intensity such as swelling, a decrease in
number and disruption of the cristae with formation of large vesicles. Amorphous
dense substance was not observed.
Left ventricle cardiac fibers from animals protected by CoQ10 showed (Fig-
ure 3C) few foci of myocardial fibers with structural changes constituted by rare
areas of loss of the myofilaments, mitochondrial swelling, with a decrease in the
Figure 3. Electron micrographs (14,380X final magnification) of left ventricular myocardium of placebo (Panel
A and B) and rats treated with CoQ10 (Panel C) showing focal loss of myofibrils (), mitochondrial swelling (),
mitochondrial swelling and cristolysis (*), clear I band enlargement (✦) and sarcoplasmic reticulum dilatation ().
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number of cristae and absence of amorphous dense deposits. Overall, the sarcom-
eres showed narrow I bands and rare lipid droplets. 
Morphometric analysis of the mitochondrial fraction area evaluated the
organelle damage in the P group and the protection offered by CoQ10 (Table).
Indeed, the mitochondrial fraction area of the animals from the CoQ10 group
(38.8±0.2%) did not differ from that of the control group animals  (33.9±0.9%)
and both were smaller (p<0.005) than that observed in placebo animals
(53.2±4.5%)
DISCUSSION
Most common literature references to profound cold cardiac effects are
related to experimental studies in the surgical setting. In this scenario, the cardiac
effects of profound cold temperature are evaluated in isolated hearts, in associa-
tion with ischemia / reperfusion and this peculiarity hinders a comparison with
our data. In addition, the reference points of temperature utilized for cold stress
test in physiological analyses conducted in intact organisms are usually markedly
higher than those achieved in the present experiments, also hampering a consis-
tent comparison with our data. As a rule, studies of cardiac effects consequent to
profound cold stress carried out in intact organisms only focus on ultrastructural
myocardial lesions. Mitochondrial and myofibrillar lesions, as was noted in the
present report, seem to be a remarkable feature in this condition. To our knowl-
edge, there is only one previous report on the functional cardiac consequences of
this situation.9) Systolic impairment and myocardial stiffness decreases were
described after profound cold stress. 
Our data have shown that exposure of rats to -15°C for four hours is fol-
lowed by marked systolic function depression with no impairment of myocardial
relaxation or passive elastic myocardial properties. In fact, although DPmax and
developed pressure / volume relations were clearly depressed, no effects on
relaxation constant and stress / strain relations were noted after cold stress. It was
Table. Mitochondrial Fractiona1 Area (%) of Control, Placebo and Rats Treated with
Ubiquinone (Co  Q10)













x ± SEM 33.87 ± 0.95 53.11 ± 4.5 *  38.78 ± 0.22§
*=p<0.05 from control. §=p<0.05 from Placebo.
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interesting that, although developed pressure values were decreased at all levels
of ventricular dilation in the hearts of stressed rats, no changes were observed in
the slope of developed pressure / volume relations; that is to say, there were no
modifications of the Frank-Starling mechanism. These results indicate that, even
though contractile capacity was depressed at all levels of myofiber lengthening,
profound cold stress did not affect length dependent activation, which bases the
Frank-Starling mechanism.26-28) This seems to be a dysfunction consequent to
impairment of maximum calcium-activated force rather than a decrease of myo-
filament calcium sensitivity.29) Aside from systolic function impairment, rat
hearts of the P group disclosed ultrastructural features that documented the pro-
found cold stress cardiac injury. Myofibrillar and mitochondrial intense disar-
rangements found in the myocardium of those rats confirmed that profound cold
stress promotes intense muscle disturbances. The mechanisms through which
whole body cold stress test triggers myocardial damage are to be more clearly
defined. We are not aware of any specific publication that has assessed heart tem-
perature in experiments of this kind, and we have not done that either. We under-
stand that studies on whole body cold stress test are conducted without that
concern because cardiac lesions are considered to be a consequence of the neuro-
humoral changes of the condition. Literature references support the assumptions
that high plasma levels and intense catecholamine myocardial synthesis play a
major role in myocardial lesions.5-8) The protection effect carried out by
propranolol4) favors such a possibility. 
There are still doubts as to whether CoQ10 administered orally is incorpo-
rated by myocardium. Some papers have reported that intracellular ubiquinone
levels do not exhibit any changes when CoQ10 is administered exoge-
nously,17,18,30,31) whereas others suggested CoQ10 incorporation.13,19,20,32) Indeed,
there are reports of exogenous CoQ10 incorporation in to cellular membranes.32)
Nevertheless, the number of papers referring to a CoQ10 myocardial protection
effect when administered orally is expressive.13,17,18,20) Functional properties pres-
ervation is reported even without CoQ10 myocardial incorporation.17) It has been
suggested that CoQ10 high plasma levels suffice for myocardial protection. In this
respect, one study reported that CoQ10 plasma levels may double on the fourth
day of exogenous administration.31) In any case, our structural data showed that
5-day oral administration of CoQ10 protects rodent myocardium against cold
stress injury. Keeping in mind that increased  adrenergic activity is the most fre-
quent hormonal disarrangement observed in profound hypothermia, it can be
assumed that the myocardial lesion occurs as a result of an oxygen suppliy /
demand ratio unbalance. Assuming the final determining factor for cold stress
induced myocardial lesion is an oxygen deficit, then it makes sense for CoQ10 to
have acted protectively, since ubiquinone's benefits have been repeatedly proven
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both for ischemia conditions1,13-19) and oxidants action. 21, 22)
In addition, although clear ultrastructural protection was accomplished, it
could be shown that exogenous CoQ10 does not protect systolic function from
profound cold injury. Indeed, our data have shown that systolic function of hearts
obtained from rats treated with exogenous administration of CoQ10 did not dis-
play any differences compared to non treated animals. Such discrepancy between
the responses from structural and functional parameters to a cellular insult is not
actually new. We can point out that the stunned myocardium example is the most
widely known for the dissociation between structural data and functional vari-
ables against an injury. In stunned myocardium, systolic and diastolic function
impairment can be observed concurrent to myocardial normal ultrastructure. In
our case, it would not seem absurd that the structural lesion in the group treated
with Co Q10 is the minimum lesion necessary to trigger the systolic dysfunction
found in both groups.  Also, the more severe lesion in the Placebo group, in addi-
tion to reaching the minimum, was not sufficient to make the dysfunction more
severe.
Our data on ultrastructure lead us to the conclusion that CoQ10 exogenous
administration protects the myocardial ultrastructure from injury resulting from
profound hypothermia. The same efficiency could not be seen as preventive
against functional changes.
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